Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
Pfizer
FEBRUARY 16, 2023
Media Contacts Pfizer Media Relations: PfizerMediaRelations@pfizer.com 212-733-1226 Investor Relations: IR@pfizer.com 212-733-4848 Valneva Laƫtitia Bachelot-Fontaine VP Global Communications & European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelot-fontaine@valneva.com Joshua Drumm, Ph.D. August 2022. Available at: [link].
Let's personalize your content